Melinta Therapeutics
Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
08 janv. 2018 07h00 HE | Melinta Therapeutics
— Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion —— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™(meropenem and...